AR and neoplasm: These epigenetic enzymes can be inhibited by a CellCentric developed compound, CCS1477, where administration of CCS1477 was shown to downregulate the expression of AR and MYC, resulting in decreased tumor growth in a 22Rv1 xenograft model of CRPC (56, 57).